{"id":"df8b9c32-49ef-5322-9ff8-2ac3d91768cb","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:eight-weeks-of-supplementation-prolongs-closure-time","predicate":"increases","statement":"Collagen-epinephrine closure time rose significantly more with nattokinase than with placebo over eight weeks in hypercholesterolemic subjects.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"39518e2b-e613-58ad-b587-c3be63bae015","mechanism_event_label":"Collagen-epinephrine closure time rose significantly more with nattokinase than with placebo over eight weeks in hypercholesterolemic subjects.","subject":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"object":{"id":"2adaff8a-0191-5c0e-afdd-f36d37e0de79","slug":"collagen-epinephrine-closure-time","display_name":"Collagen-epinephrine closure time","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"39518e2b-e613-58ad-b587-c3be63bae015","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:eight-weeks-of-supplementation-prolongs-closure-time-event","event_type":"observed_intervention","label":"Collagen-epinephrine closure time rose significantly more with nattokinase than with placebo over eight weeks in hypercholesterolemic subjects.","description":"Whole blood","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"2adaff8a-0191-5c0e-afdd-f36d37e0de79","slug":"collagen-epinephrine-closure-time","display_name":"Collagen-epinephrine closure time","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"8 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human (100 nondiabetic hypercholesterolemic subjects, 50 per arm)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase, dose not stated in the abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Randomized and placebo-controlled. Closure time is a platelet-function surrogate, not a clinical event endpoint. The dose is unavailable from the abstract, which blocks any comparison with the trials that do state FU per day. PubMed links an erratum to this article.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human (100 nondiabetic hypercholesterolemic subjects, 50 per arm)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Collagen-epinephrine closure time rose significantly more with nattokinase than with placebo over eight weeks in hypercholesterolemic subjects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The effects of nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects. (2019) https://pubmed.ncbi.nlm.nih.gov/31070609/ DOI: 10.1039/c8fo02324g Correction on record: Erratum in: Food Funct. 2019 Jul 17;10(7):4454. doi: 10.1039/c9fo90033k. PMID 31287455.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Whole blood","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"094b40aa-3758-5b18-a0b7-624c13dd8d51","evidence_kind":"source_excerpt","locator":"Lines 961-961","start_line":961,"end_line":961,"excerpt":"Collagen-epinephrine closure time rose significantly more with nattokinase than with placebo over eight weeks in hypercholesterolemic subjects.","model_system":"Human (100 nondiabetic hypercholesterolemic subjects, 50 per arm)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}